St. Jude Medical (STJ) Release: FAME II Trial Demonstrates FFR-Guided PCI Superior to Medical Treatment in Preliminary Findings
5/15/2012 10:02:44 AM
ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that data from the FAME II trial demonstrated a significant difference in the need for urgent revascularization when Fractional Flow Reserve (FFR)-guided assessment was used to direct treatment in patients with stable coronary artery disease. These highly statistically significant results validate the profound role that FFR-guided therapy has in improving patient outcomes. The preliminary data were presented at a late breaking trial session at EuroPCR.